Abstract
Background/Aims
The combination therapy of peginterferon (PEG-IFN) and ribavirin is the standard treatment for hepatitis C virus (HCV) infection. However, few trials have involved patients with cirrhosis. The purpose of this study was to elucidate the efficacy and safety of treatment with PEG-IFN and ribavirin in patients with cirrhosis associated with HCV infection. Method: A total of 65 patients were treated with PEG-IFN alpha-2a/ribavirin (n=32) or PEG-IFN alpha-2b/ribavirin (n=33). PEG-IFN alpha-2a and PEG-IFN alpha-2b were administered at doses of 180 μg/week and 1.5 μg/kg/week, respectively, and ribavirin was administered orally at doses of 800-1200 mg. Patients with HCV genotype 1 and genotype non-1 were treated for 48 and 24 weeks, respectively. The treatment response was assessed based on the sustained virologic response (SVR). Results: The early virologic response (EVR), end-of-treatment response (ETR), and SVR were 70.0%, 52.0%, and 24.0%, respectively, in genotype 1 (n=50). In genotype non-1 (n=15), the ETR was 53.3% and the SVR was 33.3%. The overall SVR did not differ with genotype (1vs non-1, 24.0%vs.33.3%; P=0.471) or between decompensated cirrhosis and compensated cirrhosis (20.0%vs.27.3%, P=0.630). Ten patients developed cirrhotic complications during the treatment, and 11 stopped treatment due to treatment -related adverse events. Conclusion: The combination therapy of PEG-IFN and ribavirin exhibited a low efficacy in cirrhotic patients with HCV infection and was associated with frequent serious complications. However, with careful management of complications, the therapy may have a considerable efficacy in some patients with cirrhosis and HCV infection. (Korean J Hepatol 2010;16:38-48
Citations
Citations to this article as recorded by
- Favorable Outcomes of Chinese HCV-Related Cirrhotic Patients with Sustained Virological Response after Pegylated Interferon Plus Ribavirin Treatment
Geng-lin Zhang, You-ming Chen, Ting Zhang, Qing-xian Cai, Xiao-hong Zhang, Zhi-xing Zhao, Chao-shuang Lin, Zhi-liang Gao
BioMed Research International.2017; 2017: 1. CrossRef - Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Patients with Decompensated Cirrhosis
Geum-Youn Gwak
The Korean Journal of Gastroenterology.2016; 67(3): 137. CrossRef - KASL clinical practice guidelines: management of hepatitis C
Clinical and Molecular Hepatology.2016; 22(1): 76. CrossRef - Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C
Chang Ho Jung, Soon Ho Um, Tae Hyung Kim, Sun Young Yim, Sang Jun Suh, Hyung Joon Yim, Yeon Seok Seo, Hyuk Soon Choi, Hoon Jai Chun
Gut and Liver.2016; 10(5): 808. CrossRef - Treatment of Hepatitis C in Special Conditions: Liver Cirrhosis
Geum-Youn Gwak
Korean Journal of Medicine.2015; 88(6): 643. CrossRef - Pegylated interferon α‐2a plus ribavirin for decompensated hepatitis C virus‐related cirrhosis: relationship between efficacy and cumulative dose
Yan Xu, Wenqian Qi, Xu Wang, Ping Zhao, Yonggui Zhang, Qian Zhang, Shaoyou Qin, Jiangbin Wang
Liver International.2014; 34(10): 1522. CrossRef - KASL clinical practice guidelines: Management of Hepatitis C
Clinical and Molecular Hepatology.2014; 20(2): 89. CrossRef - Clinical and epidemiological features of hepatitis C virus infection in South Korea: A prospective, multicenter cohort study
Mun Hyuk Seong, Ho Kil, Young Seok Kim, Si Hyun Bae, Youn Jae Lee, Han Chu Lee, Byung Hak Kang, Sook-Hyang Jeong
Journal of Medical Virology.2013; 85(10): 1724. CrossRef - A Case of Interstitial Pneumonitis and Pancytopenia Following the Combination Therapy of Pegylated Interferon and Ribavirin
Ji-Hyun Suh, Sung Hwahn Hahn, Ji Eun Lee, Jin Hyung Han, Kyung-Mook Kim, Doh-Hyung Kim, Yon-Seop Kim, Jae-Suk Park, Young-Koo Jee
Tuberculosis and Respiratory Diseases.2011; 70(1): 69. CrossRef
